Securities code: Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) Announcement No.: 2022022
Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317)
Announcement on the resolution of the first holders’ meeting of the employee stock ownership plan in 2022
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) (hereinafter referred to as “the company”) the first meeting of the holders of the 2022 employee stock ownership plan was held in the company’s conference room on March 4, 2022 by means of on-site and communication voting. The number of holders attending this meeting is 25, representing 31.806 million shares of the company’s employee stock ownership plan in 2022, accounting for 100% of the total share. The meeting was convened and presided over by Mr. Li Tao, Secretary of the board of directors of the company. The convening and holding of this meeting comply with laws, regulations and relevant provisions of the company’s employee stock ownership plan in 2022. After careful deliberation and voting by open ballot, the following resolutions are made:
1、 The proposal on the establishment of the company’s 2022 ESOP Management Committee was reviewed and approved. In accordance with the relevant provisions of the employee stock ownership plan of Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) 2022 and the measures for the administration of the employee stock ownership plan of Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) 2022, the company established a management committee for the employee stock ownership plan of 2022 to act as the daily management and supervision organization of the employee stock ownership plan and exercise shareholders’ rights on behalf of all shareholders. The management committee is composed of three members and one chairman of the management committee. The term of office of the members of the management committee is the duration of the employee stock ownership plan.
Voting results: there were 31.806 million consents, accounting for 100% of the total shares held by the holders attending the holders’ meeting, 0 objections and 0 abstentions.
2、 The proposal on electing members of the Management Committee of the company’s employee stock ownership plan in 2022 was deliberated and adopted.
At this meeting, long Chunhua, Liu Shuang and Huang Hougan were elected as members of the company’s 2022 ESOP Management Committee. The term of office is consistent with the duration of the employee stock ownership plan in 2022.
Long Chun, director, vice president and chief financial officer of Huawei, is the leader of long Chaofeng, director and senior vice president of the company
Securities code: Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) Announcement No.: 2022022
Sister; Liu Shuang is the vice president of the company. In addition to the foregoing, the members of the management committee have no relationship with the shareholders holding more than 5% of the company, the actual controllers, and other directors, supervisors and senior managers of the company. Voting results: there were 31.806 million consents, accounting for 100% of the total shares held by the holders attending the holders’ meeting, 0 objections and 0 abstentions.
On the same day, the 2022 ESOP Management Committee of the company held its first meeting to elect the chairman of the 2022 ESOP Management Committee of Longchun Huawei, whose term of office is consistent with the duration of the company’s 2022 ESOP.
3、 The proposal on Authorizing the company’s 2022 ESOP Management Committee to handle matters related to this ESOP was reviewed and approved.
According to the relevant provisions of the employee stock ownership plan of Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) 2022 and the measures for the administration of the employee stock ownership plan of Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) 2022, the meeting of the holders of the employee stock ownership plan authorizes the Management Committee of the employee stock ownership plan of 2022 to handle the relevant matters of the employee stock ownership plan. The specific authorized matters are as follows:
(1) Be responsible for convening the shareholders’ meeting;
(2) Daily management of ESOP on behalf of all holders;
(3) Exercise shareholders’ rights on behalf of all shareholders;
(4) Manage the benefit distribution of the employee stock ownership plan, and decide on the sale and distribution of the underlying shares when the lock-in period of the underlying shares involved in the employee stock ownership plan expires, expires, liquidates, terminates in advance, etc;
(5) Decide the disqualification of the holder and the disposal of the shares held by the disqualified holder in accordance with the provisions of the employee stock ownership plan, including the increase of the holder and the change of the holder’s share;
(6) Make decisions on the ownership of shares repurchased and forcibly recovered by the employee stock ownership plan, as well as the grant, distribution and recovery of relevant shares and the determination of relevant prices;
(7) Handle share registration and inheritance registration of employee stock ownership plan;
(8) Make decisions on special matters other than the above matters during the duration of the employee stock ownership plan;
(9) Sign relevant documents on behalf of all holders;
(10) Other duties authorized by the shareholders’ meeting;
(11) Other duties to be performed by the management committee as agreed in the draft plan and relevant laws and regulations. This authorization starts from the date of approval of the first holders’ meeting of the company’s employee stock ownership plan in 2022 to the date of approval of the company
Securities code: Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) Announcement No.: 2022022
The employee stock ownership plan will be effective on the date of termination in 2022.
Voting results: there were 31.806 million consents, accounting for 100% of the total shares held by the holders attending the holders’ meeting, 0 objections and 0 abstentions.
It is hereby announced.
Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) board of directors March 4, 2002
